Chimerix (NASDAQ:CMRX) Shares Cross Below 50 Day Moving Average of $3.42

Chimerix Inc (NASDAQ:CMRX) passed below its 50-day moving average during trading on Thursday . The stock has a 50-day moving average of $3.42 and traded as low as $3.54. Chimerix shares last traded at $3.66, with a volume of 5,165 shares traded.

A number of research analysts recently commented on the company. Cowen restated a “hold” rating and issued a $3.00 price target on shares of Chimerix in a research report on Thursday, May 9th. ValuEngine cut Chimerix from a “hold” rating to a “sell” rating in a research report on Wednesday, May 1st. Zacks Investment Research lowered Chimerix from a “hold” rating to a “sell” rating in a research note on Friday, May 10th. Finally, Citigroup reduced their price objective on Chimerix from $4.25 to $2.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 6th. Three research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Chimerix currently has a consensus rating of “Hold” and an average target price of $4.75.

The stock’s 50 day moving average price is $3.46. The firm has a market capitalization of $185.39 million, a price-to-earnings ratio of -3.02 and a beta of 1.08.

Chimerix (NASDAQ:CMRX) last released its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.35) earnings per share for the quarter, meeting the consensus estimate of ($0.35). The business had revenue of $2.36 million for the quarter, compared to analyst estimates of $2.00 million. Chimerix had a negative return on equity of 36.85% and a negative net margin of 757.77%. As a group, sell-side analysts predict that Chimerix Inc will post -1.02 EPS for the current year.

In other Chimerix news, Director Martha J. Demski acquired 18,000 shares of Chimerix stock in a transaction that occurred on Tuesday, May 28th. The shares were acquired at an average cost of $3.60 per share, with a total value of $64,800.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Michael A. Sherman acquired 30,000 shares of Chimerix stock in a transaction that occurred on Monday, May 20th. The stock was acquired at an average cost of $3.48 per share, for a total transaction of $104,400.00. The disclosure for this purchase can be found here. Insiders purchased 78,000 shares of company stock worth $256,800 over the last ninety days. 12.50% of the stock is currently owned by insiders.

Hedge funds have recently made changes to their positions in the company. SG Americas Securities LLC acquired a new stake in shares of Chimerix during the fourth quarter valued at about $26,000. HRT Financial LLC acquired a new stake in shares of Chimerix during the fourth quarter valued at about $40,000. Pitcairn Co. acquired a new stake in shares of Chimerix during the fourth quarter valued at about $42,000. Citigroup Inc. boosted its stake in shares of Chimerix by 81.2% during the fourth quarter. Citigroup Inc. now owns 19,570 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 8,771 shares in the last quarter. Finally, Paloma Partners Management Co acquired a new stake in shares of Chimerix during the fourth quarter valued at about $71,000. 69.71% of the stock is currently owned by hedge funds and other institutional investors.

Chimerix Company Profile (NASDAQ:CMRX)

Chimerix, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients.

Featured Article: Is a Roth IRA right for you?

Receive News & Ratings for Chimerix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix and related companies with MarketBeat.com's FREE daily email newsletter.